Full video transcriptClick to expand
Auto-generated transcript of @lovethyliverr's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00It is turned zippy Tuesday, which means it is time to jab.
- 0:02I'm 22 pounds down and this is how I do it.
- 0:05Last week I did my stomach.
- 0:06So this week we're gonna do the back of the arm.
- 0:09Last week I kind of talked to you guys
- 0:10about how I've been micro dosing
- 0:12before jumping up to the next milligram in dosing.
- 0:14Last week I was on 7.5 milligrams.
- 0:16So I did 7.5 on Tuesday on Friday, did 2.5.
- 0:19Since I'm getting ready to jump up to 10 milligrams
- 0:22that way I can kind of see
- 0:23how my body's going to react to it.
- 0:24And I have been doing this for the past two months
- 0:26and I love it.
- 0:28This is what I have left in my 7.5 milligram vial.
- 0:30We're gonna see if we can get the full 50 units out.
- 0:33And if I can, I'm going to do the micro dose again this week.
- 0:36Very important that you make sure that you clean
- 0:38the top of your vial before extracting your medication.
- 0:41Better safe than sorry, clean, clean, clean.
- 0:42Pro tip, however much medication you're going to be extracting,
- 0:46put in that same amount of air
- 0:48to equalize the pressure inside the vial.
- 0:50This makes getting the medication out seamless.
- 0:52This is a one milliliter vial.
- 0:54I need half of this, so 50 units.
- 0:56Go in at a 45 degree angle.
- 0:58This is going to help prevent you
- 0:59from getting any of the silicone or rubber
- 1:01inside the syringe.
- 1:03Inject the air.
- 1:05Pull back to the amount of medication you want to extract.
- 1:08In my case, 50 units.
- 1:10Watch as it just fills itself up.
- 1:13Science is so cool.
- 1:14I always remove the syringe like that
- 1:16to avoid any of the medication dripping out.
- 1:18A couple of flicks to get all the bubbles to the top.
- 1:20And when you see the bead, you know you're good to go.
- 1:23Another stand pro tip.
- 1:24Warm up the medication before injecting.
- 1:26In my experience, this has helped me avoid
- 1:29any of the localized reactions.
- 1:31Swelling, itching, redness, et cetera.
- 1:33Is it foolproof?
- 1:34No, is it going to work for you?
- 1:35I hope so, but it's worked for me every single time.
- 1:37I'm not actually going to videotape
- 1:39giving myself the injection
- 1:40because TikTok has batten down the hatches,
- 1:42but I'm going to show you how it makes it easier
- 1:44to give yourself an injection on the back of the arm.
- 1:46There's two ways.
- 1:47One, take a cylindrical object.
- 1:49In this case, I'm using this boulogeré.
- 1:51Don't even know if I've pronounced that correct.
- 1:53Body mist.
- 1:55This is the phrase, meringue.
- 1:56So good.
- 1:57You're going to put your cylindrical object
- 1:58underneath your arm like this.
- 2:00Closer your orders are interested in the needle,
- 2:01the more control you have.
- 2:02So you're just going to pop it in, push it in.
- 2:06No cylindrical device.
- 2:07No problem.
- 2:08You're just going to need one more ball than usual, okay?
- 2:10Arm up, fat, right in.
- 2:14Pick your point.
- 2:15Always make sure you clean the area
- 2:16before putting in your injection.
- 2:19Just binding my own business here.
- 2:22Now it's time to do my other peptides,
- 2:23and I will see you next Tuesday.
GLP-1 self-care content: hype vs. what the data shows
Quick answer
The creator is using tirzepatide, likely compounded, from a multi-dose vial and has self-modified her dosing schedule to split weekly doses across two injections as she approaches a 10 mg dose level. This departs from the once-weekly subcutaneous protocol evaluated in SURMOUNT trials and reviewed by the FDA for Zepbound approval. No clinical data currently supports a split-dose tirzepatide regimen for weight management, and the pharmacokinetic implications of twice-weekly dosing have not been studied in this population.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 self-care content: hype vs. what the data shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 self-care content: hype vs. what the data shows" from Samantha Brown 🌸 Liver Health. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is using tirzepatide, likely compounded, from a multi-dose vial and has self-modified her dosing schedule to split weekly doses across two injections as she approaches a 10 mg dose level.
The reason this review is not generic is the source wording and the canonical claim label "glp1 we love a self care day don t forget that samantha50 saves y." In this clip, the useful excerpt is: "It is turned zippy Tuesday, which means it is time to jab." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is using tirzepatide, likely compounded, from a multi-dose vial and has self-modified her dosing schedule to split weekly doses across two injections as she approaches a 10 mg dose level.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is using tirzepatide, likely compounded, from a multi-dose vial and has self-modified her dosing schedule to split weekly doses across two injections as she approaches a 10 mg dose level. This departs from the once-weekly subcutaneous protocol evaluated in SURMOUNT trials and reviewed by the FDA for Zepbound approval. No clinical data currently supports a split-dose tirzepatide regimen for weight management, and the pharmacokinetic implications of twice-weekly dosing have not been studied in this population.
- Tirzepatide's approved dosing in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) is once-weekly subcutaneous injection with four-week escalation intervals, not a split twice-weekly schedule.
- No published study has evaluated a split-dose or microdosing tirzepatide protocol for managing side effects or dose escalation in weight management patients.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide's approved dosing in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) is once-weekly subcutaneous injection with four-week escalation intervals, not a split twice-weekly schedule.
- No published study has evaluated a split-dose or microdosing tirzepatide protocol for managing side effects or dose escalation in weight management patients.
- Tirzepatide has an approximate five-day half-life, meaning twice-weekly dosing creates a pharmacokinetic profile that differs from the studied once-weekly regimen in ways that are not yet characterized.
- Warming injectable medications before use is supported for reducing injection site discomfort in some drug classes (Usach et al., 2019, Advances in Therapy), though tirzepatide-specific data are limited.
- Compounded tirzepatide drawn from multi-dose vials is not FDA-reviewed for sterility or potency on a per-product basis, and is not equivalent to FDA-approved Zepbound or Mounjaro.
- The FDA issued guidance in 2024 flagging safety concerns with compounded GLP-1 medications, including questions about concentration accuracy and sterility in compounded vial products.
- Any modification to a prescribed tirzepatide dosing schedule, including splitting doses, should be discussed with the prescribing clinician, not self-directed based on social media content.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @lovethyliverr actually say?
The creator, 22 pounds into a tirzepatide journey, walked through her entire injection routine on camera. She described a self-directed "microdosing" protocol, splitting doses across Tuesday and Friday rather than following a standard weekly schedule. She's currently at 7.5 mg and preparing to move to 10 mg, using the split-dose approach to "see how my body's going to react." She also covered injection technique in detail, including the 45-degree needle angle, equalizing vial pressure with air, warming the medication before injection, and using a cylindrical object to stabilize the arm for self-injection. The video closes with a mention of "other peptides," though no details are given.
Does the science back this up?
The injection mechanics she describes are largely sound. The microdosing protocol, however, is entirely self-invented and has no clinical trial support. Full stop.
Tirzepatide's approved dosing schedule, studied in the SURMOUNT-1 and SURMOUNT-2 trials (Jastreboff et al., 2022, NEJM; Wadden et al., 2023, NEJM), is once-weekly subcutaneous injection, with dose escalation at four-week intervals under a prescriber's guidance. Those trials did not test split-dose or twice-weekly regimens. The half-life of tirzepatide is approximately five days (Lilly prescribing information), which means twice-weekly dosing creates a meaningfully different pharmacokinetic profile than what was studied. Whether that difference is beneficial, neutral, or harmful is unknown. The creator's logic, that smaller repeated doses help her "see how my body's going to react," is understandable from a lay perspective, but it's not a validated titration strategy.
On technique: the 45-degree angle recommendation for subcutaneous injection is appropriate for shorter needles or patients with less subcutaneous tissue. The air-equalization trick for multi-use vials is a legitimate nursing technique. Warming medication before injection has some support for reducing injection site discomfort (Usach et al., 2019, Advances in Therapy), though evidence specific to tirzepatide is limited.
What did they get wrong (or right)?
Credit where it's due: her sterile technique reminders, clean the vial top, clean the injection site, are correct and worth repeating. Bubble removal and the cylindrical object trick for dorsal arm injections are practical and not harmful.
What she got wrong, or at least what she's presenting without appropriate caveats, is framing a self-designed split-dose protocol as a usable template for her 11,000+ viewers. Saying "I have been doing this for the past two months and I love it" is anecdote, not evidence. Tirzepatide is a prescription medication with dose escalation schedules set by a clinician for a reason. Deviating from those schedules, especially using compounded tirzepatide drawn from vials (which is what this appears to be), introduces variables that a prescriber can't monitor if they don't know it's happening.
The mention of "other peptides" at the end is vague but worth flagging. Combining GLP-1 receptor agonists with other peptides without clinical supervision is not something viewers should replicate based on a TikTok, regardless of the creator's personal experience.
What should you actually know?
If you're on tirzepatide or considering it, the injection technique tips here are mostly fine to watch. The dosing improvisation is not something to copy without talking to whoever prescribes your medication.
Tirzepatide acts on both GIP and GLP-1 receptors. Its pharmacokinetics were designed around weekly dosing. A prescriber-supervised titration schedule, starting at 2.5 mg weekly and increasing every four weeks as tolerated, exists precisely to manage gastrointestinal side effects and cardiovascular stress during dose increases. If you're experiencing reactions that make you want to split your dose, that is a conversation to have with your prescriber, not a problem to self-engineer around.
Compounded tirzepatide, which is what multi-dose vials typically indicate, is not the same as FDA-approved Zepbound or Mounjaro. Compounded formulations are not FDA-reviewed for safety, efficacy, or sterility on a product-by-product basis. The FDA has flagged concerns about compounded GLP-1 medications specifically (FDA Drug Shortages guidance, 2024). Viewers drawing medication from vials at home should understand that distinction clearly.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Samantha Brown 🌸 Liver Health · TikTok creator
11.4K views on this video
We love a self care day. Don’t forget that SAMANTHA50 saves you 50 at the 🔗 in b!0. 🫶🏼✨ #glp1 #glp1community #tirzepatidejourney #newyearnewme
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide's approved dosing in surmount-1 (jastreboff et al., 2022, nejm)?
Tirzepatide's approved dosing in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) is once-weekly subcutaneous injection with four-week escalation intervals, not a split twice-weekly schedule.
What does the video say about no published study has evaluated a split-dose?
No published study has evaluated a split-dose or microdosing tirzepatide protocol for managing side effects or dose escalation in weight management patients.
What does the video say about tirzepatide has an approximate five-day half-life, meaning twice-weekly dosing creates?
Tirzepatide has an approximate five-day half-life, meaning twice-weekly dosing creates a pharmacokinetic profile that differs from the studied once-weekly regimen in ways that are not yet characterized.
What does the video say about warming injectable medications before use?
Warming injectable medications before use is supported for reducing injection site discomfort in some drug classes (Usach et al., 2019, Advances in Therapy), though tirzepatide-specific data are limited.
What does the video say about compounded tirzepatide drawn from multi-dose vials?
Compounded tirzepatide drawn from multi-dose vials is not FDA-reviewed for sterility or potency on a per-product basis, and is not equivalent to FDA-approved Zepbound or Mounjaro.
What does the video say about the fda?
The FDA issued guidance in 2024 flagging safety concerns with compounded GLP-1 medications, including questions about concentration accuracy and sterility in compounded vial products.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Samantha Brown 🌸 Liver Health, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.